Intellia Stock Price Target: $30 Maintained - Nov 13

The Story

Citizens maintained its $30 price target for Intellia Therapeutics ($NTLA) in connection with HAE data, according to the source report. The available information doesn't include the analyst's rationale, a current Nov. 13 share price, or details about the data.

The supplied quote puts Intellia at $11.26, up $0.05, or 0.45%, as of Oct. 26, 2026, at 20:00 UTC. That dated snapshot isn't a current market quote.

Why It Matters For Your Portfolio

• The $30 target is an analyst view, not a guarantee. Without the report's supporting assumptions or a current share price, you can't use it to assess present implied upside.
• The source identifies HAE data as the basis for maintaining the target, but provides no trial results or patient counts. That limits how much you can conclude about the clinical evidence.
• Additional positive clinical and patient-reported data for Lonvogur is listed as a catalyst. No release date is supplied, so its timing remains uncertain.
• Other figures in the supplied material include 34.51%, 19.08%, and 0.68%, but their metrics aren't identified. They can't be reliably interpreted or compared with the 0.45% move in the dated quote.

The Trade

Biotechnology growth investors and traders tracking clinical catalysts may want to follow the full Citizens note and Intellia's next Lonvogur data update. The available sources don't provide a date for that update or enough detail to evaluate the underlying HAE results, so the $30 target alone offers limited context. This is informational analysis, not a recommendation to buy, sell, or hold $NTLA.